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We conducted a phase I trial of allogeneic T cells sensitized in vitro against a pool of pentadecapeptides
(15-mer peptides) spanning the sequence of CMVpp65 for adoptive therapy of 17 allogeneic hematopoietic
cell transplant recipients with cytomegalovirus (CMV) viremia or clinical infection persisting despite
prolonged treatment with antiviral drugs. All but 3 of the patients had received T celledepleted transplants
without graft-versus-host disease (GVHD) prophylaxis with immunosuppressive drugs after trans-
plantation. The CMVpp65-speciﬁc T cells (CMVpp65CTLs) generated were oligoclonal and speciﬁc for only 1
to 3 epitopes, presented by a limited set of HLA class I or II alleles. T cell infusions were well tolerated
without toxicity or GVHD. Of 17 patients treated with transplant donor (n ¼ 16) or third-party (n ¼ 1)
CMVpp65CTLs, 15 cleared viremia, including 3 of 5 with overt disease. In responding patients, the
CMVpp65CTLs infused consistently proliferated and could be detected by T cell receptor Vb usage in
CMVpp65/HLA tetramer þ populations for period of 120 days to up to 2 years after infusion. Thus,
CMVpp65CTLs generated in response to synthetic 15-mer peptides of CMVpp65 are safe and can clear
persistent CMV infections in the post-transplantation period.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Cytomegalovirus (CMV) infections remain a major cause
of morbidity and mortality in allogeneic hematopoietic cell
transplant (HCT) recipients [1,2]. Although prophylactic or
preemptive treatment with ganciclovir or foscarnet has
reduced the incidence and mortality of early CMV infections,
prolonged antiviral treatment may delay recovery of virus-
speciﬁc immune responses and predispose patients to late-
onset disease [2-5]. Furthermore, treatment with antiviral
drugs often cannot be sustained because of complicating
myelosuppression or nephrotoxicity [2].
Reconstitution of CMV-speciﬁc CD8þ cytotoxic T cells
(CMVCTLs) after HCT is correlated with control of CMVdgments on page 1676.
requests: Guenther Koehne, MD, PhD,
tion Service, Division of Hematologic
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rk, NY 10065.
c.org (G. Koehne).
15.05.015
ty for Blood and Marrow Transplantation.infections [2,6-14]. Riddell et al. [15,16] ﬁrst demonstrated
that adoptive transfer of donor-derived CD8þ CMVCTL clones
sensitized with autologous CMV-infected ﬁbroblasts could
protect allogeneic marrow recipients from infection. Subse-
quent studies employing CMV-speciﬁc, predominantly CD8þ,
T cell lines sensitized with autologous dendritic cells (DCs) or
peripheral blood mononuclear cells (PBMCs) loaded with
lysates of CMV-infected cells [17,18] or single peptides of
immunodominant antigens, such as CMVpp65 [19] or DCs
transduced to express immunogenic CMV proteins [20], have
further documented the potential of such cells to prevent or
treat CMV disease. However, regulatory concerns persist
regarding the use of infected cell lysates or virus-transduced
cells. Similarly, sensitization with single peptides presented
by speciﬁc HLA alleles, however prevalent, may limit their
broad application.
We previously reported a method for generating CMVCTL
by sensitization with autologous DCs loaded with a pool of
138 synthetic pentadecapeptides (15-mers) with 11 amino
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G. Koehne et al. / Biol Blood Marrow Transplant 21 (2015) 1663e16781664acid overlaps spanning the amino acid sequence of CMVpp65
[21]. With this approach, wewere able to generate CMVpp65
peptideespeciﬁc Tcell lines (CMVpp65CTLs) from each CMV-
seropositive donor tested, regardless of HLA type, and to
characterize these lines as to their epitope speciﬁcities and
HLA restrictions [21]. We now report results of a phase I trial
reassessing the safety and antiviral activity of escalating
doses of transplant donor-derived CMVpp65CTLs generated
by this technique in allogeneic HCT recipients with CMV
infections or persistent CMV viremia. By deﬁning the epitope
speciﬁcity, HLA restriction, and TCR Vb usage of the T cells
infused, we were also able to sequentially follow their
growth and persistence in vivo and correlate their expansion
with clearance of infection.
MATERIALS AND METHODS
Design of Clinical Trial
This single-institution phase I trial was designed to assess the toxicity
and activity of escalating doses of CMVpp65CTLs derived from T cell lines
generated from CMV-seropositive healthy marrow transplant donors by
sensitization in vitro with autologous, cytokine-activated monocytes
(CAMS) loaded with a pool of synthetic 15-mer peptides spanning the
sequence of CMV protein pp65 [21]. The trial was approved by the institu-
tional review/privacy board at Memorial Sloan-Kettering Cancer Center, the
National Marrow Donor Program, and the Food and Drug Administration.
Eligible patients were allogeneic HCT recipients who either had clinical CMV
infection or CMV viremia that was persistent despite at least 2 weeks of
treatment with antiviral drugs or those who could not be maintained on
antiviral drugs because of associated toxicities.
Four dose levels of transplant donor-derived CMVpp65CTLs were
sequentially evaluated: group 1 (n ¼ 3) received 5  105 T cells/kg; group 2
(n¼ 4),1106 Tcells/kg 1 dose; group 3 (n¼ 3), 2106 Tcells/kg 1 dose;
group 4 (n ¼ 6), 1  106 T cells/kg  3 weekly doses. Endpoints included
incidence and severity of toxicities and acute graft-versus-host disease
(GVHD) as well as the clinical and virological responses observed and their
correlation with alterations in CMV-speciﬁc T cells detected after infusion.
Patient and Donor Characteristics
Characteristics of the 16 patients who received transplant donor-
derived CMVpp65CTLs, including diagnoses, disease status at time of
transplantation, conditioning regimen, and type of transplantation, are
summarized in Table 1. All recipients were CMV-seropositive before
transplantation.
All patients had been previously treated with antiviral drugs, according
to standard of care before administration of CMVpp65CTLs. Antiviral ther-
apy was maintained after CMVpp65CTL infusion in 13 patients but had been
discontinued in 4 patients (unique patient numbers [UPN] 4, 5, 8, and 11)
because of intolerable toxicities at time of CMVpp65CTL infusion.
UPN 17 was referred from an outside center with reactivation of drug-
resistant CMV after a 9/10 HLA-matched (HLA-A mismatch) HCT from a
seronegative unrelated donor. This patient was treated with partially
matched third-party CMV cytotoxic T cells (CTLs) under an institutional re-
view board and Food and Drug Associationeapproved single patient use-IND.
Generation of Antigen-Presenting Cells
Autologous transplant donor-derived CAMS and Epstein-Barr viruse-
transformed B lymphocyte cell lines (EBV-BLCLs) were generated as previ-
ously described [21-24]. To identify HLA restrictions of CMVpp65CTL, a
panel of EBV-BLCLs of deﬁned HLA types were generated as previously
described [21,22].
Generation of Clinical Grade CMVpp65CTLs
Cultures of CMVpp65-speciﬁc T cells from seropositive transplant do-
nors were initiated at ﬁrst detection of CMV viremia or before reactivation
for seropositive transplant recipients at risk. CD3þ-enriched T cell fractions,
isolated from PBMC by depletion of adherent monocytes and immu-
noadsorption of natural killer cells, were initially stimulated at an effector to
stimulator ratio of 20:1 with irradiated (6000 cGy) autologous CAMS loaded
with the pool of overlapping pentadecapeptides of CMVpp65 (Invitrogen,
Boston, MA) and propagated in vitro with weekly restimulation at an
effector to stimulator ratio of 4:1 and supplementation with IL-2 beginning
at day 10 to 16, as previously described [21,22]. After 28 days, T cells were
harvested, counted, and tested for antigen-speciﬁc cytotoxicity and lack of
alloreactivity [21-23] as well as for microbiological sterility and endotoxin
levels. Aliquots of CMVpp65CTLs meeting release criteria were
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when indicated.
Characterization of CMVpp65CTL Lines and Monitoring of CMV-speciﬁc
T Cell Responses
Yields of CD4þ and CD8þ T cells and content of CD3 CD56þ natural
killer cells and CD20þ B cells were quantitated in each culture. IFN-gþ CD8þ
and/or CD4þ CMVpp65-speciﬁc T cells were quantitated using a modiﬁca-
tion of the techniques of Waldrop et al. [25] as previously described [21-23].
Quantitation of tetramerþ T cells was performed using CMVpp65 MHC-
peptide tetramers for HLA A*0201, A*2402, and B*0702 bearing peptide
sequences NLVPMVATV, QYDPVAALF, RPHERNGFTV, and TPRVTGGGAM
respectively (Beckman Coulter, Fullerton, CA) as previously described [22].
Functional Characterization and Epitope Mapping by Intracellular IFN-
gamma Assay
Epitope identiﬁcationwas performed using a mapping grid of CMVpp65
peptide subpools as previously described [21]. T cell responses to speciﬁc
peptides or subpools of CMVpp65 were quantitated by measuring the
number of IFN-gþ T cells generated upon secondary stimulation with
autologous peptide-loaded antigen-presenting cells [21-23].
Cytotoxicity of CMVpp65CTLs In Vitro
CMVpp65CTLs were assessed for their capacity to lyse CMVpp65 loaded
targets using a standard 51chromium release assay [23,24]. Targets used in all
experiments included peptide-loaded and unloaded autologous and fully
allogeneic phytohemagglutinin (PHA) blasts. To deﬁne the HLA restriction of
epitope-speciﬁc CMVpp65CTLs, the cytotoxic activity wasmeasured against a
panel of EBV-BLCL or PHA blasts loaded with the peptide, each sharing with T
cells of a given donor a single HLA allele, as previously described [21,24].
Analysis of TCR Vb Repertoire within CMVpp65CTL
The CMVpp65 peptide-HLA tetramerþ T cells contained within each
CMVpp65CTL line were analyzed for TCR Vb repertoire by ﬂuorescent acti-
vated cell sorter, as previously described [22], using a commercially available
kit (IO Test Beta Mark, Beckman Coulter, France) according to procedures
provided by the manufacturer [26].
Monitoring of Patients and Follow-up after CMV CTL Infusion
Patients were sequentially monitored for toxicities using the Common
Terminology Criteria for Adverse Events (version 4, 2009) and for acute
GVHD as graded by the Center for International Blood and Marrow Trans-
plant Research Consensus [27].
CMV in the blood was measured by quantitation of CMV antigenemia in
the initial 8 patients and by CMV polymerase chain reaction thereafter, using
methods previously described [28-31]. CMV levels were monitored before
the T cell infusion, at weekly intervals for 6 weeks thereafter and monthly
until clearing or clinical progression.
T cell responsesweremeasured by quantitating IFNgþ Tcells in response
to the total pool of CMVpp65 peptides as previously described [21,22]. The
CMVpp65 epitope speciﬁcations and HLA restrictions of the T cells in the
blood were identiﬁed as discussed above. After infusion of T cells known to
contain CMV peptide/HLA tetramerþ T cells, the tetramerþ T cells were also
monitored by ﬂuorescent activated cell sorter [21,22]. In addition, the TCR Vb
repertoires of the tetramerþ cells or IFNgþ CMVpp65CTLs were character-
ized both in the CMVpp65CTLs infused and sequentially in the patient.
RESULTS
Patient Status before Infusion of CMVpp65CTLs
Of the 16 patients treated with transplant donorederived
CMVpp65CTLs after allogeneic HLA-matched related (n¼ 12)
or unrelated (n ¼ 4) HCT, 2 (UPNs 1 and 2) received un-
modiﬁed allogeneic HCT with post-transplantation immu-
nosuppressive drugs as GVHD prophylaxis. UPN 1 was on
standard doses of cyclosporine A and mycophenolate mofetil
at time of treatment. UPN 2 was being treated for active
GVHD, grade III, of skin and gut with cyclosporine A 200 mg
every 12 hours, mycophenolate mofetil 1 gm every 12 hours,
andmethylprednisolone .5 mg/kg daily. Patients 3 through16
received T celledepleted HCT without immunosuppressive
drugs to prevent GVHD. UPN 13 had been treated with
parenteral steroids for grade II acute GVHD of the gut before
CTL infusion, but by the time of CTL infusion, the patient was
off all immune suppression.
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treatment with antiviral drugs before adoptive transfer of
CMVpp65CTLs and had either not responded or was intol-
erant to further drug therapy. The median time to CMV
reactivation after allogeneic HCT was 36 days (range, 0 to 94
days). The median time to ﬁrst treatment with
CMVpp65CTLs after allogeneic HCT was 120 days (range, 78
to 164 days). All patients had persistent CMV viremia at time
of treatment with CMVpp65CTLs. Three patients (UPNs 1, 6,
7) had concurrent interstitial pneumonia but biopsy or
bronchoalveolar lavage was refused before treatment. Two
patients (UPNs 5 and 9) were diagnosed with CMV retinitis,
including 1 with meningoencephalitis (UPN 19).
Characterization of T Cells Infused
CMVpp65CTLs were predominantly CD8þ in 14 of 15 lines
tested (Table 3). Tetramerþ CMVpp65CTLs were primarily
(97%) of the CD62L, CCR7, CD45RO effector memory
phenotype. However, small populations of tetramerþ
CD62Lþ, CCR7þ, CD45RO Tcentral memory cells were detected in 6
of 8 lines tested.
Responding T cells were speciﬁc for a single pentadeca-
peptide derived from CMVpp65 in 9 of 15 cases adequately
tested (Table 3). The peptide epitopes identiﬁed in these 9
lines and their presenting HLA alleles are described in
Table 3. Six lines (UPNs 6, 7, 9, 11, 12, 14) contained IFNgþ T
cells speciﬁc for more than 1 CMVpp65 epitope. One line
contained CD8þ T cells speciﬁc for 2 epitopes; the NLV pep-
tide presented by HLA-A*0201 elicited the dominant
response and the QARLTVSGLA peptide presented by HLA-
B*5201 induced a lesser or subdominant response. In 5
lines, a single CMVpp65 pentadecapeptide contained a
nonamer presented by a class I and an overlapping 11-mer
presented by a class II HLA allele shared by the donor that
elicited CD8þ and CD4þ T cell responses, respectively. The
proportion of IFNgþ T cells contained in the CTL lines speciﬁc
for each epitope varied, ranging from 1.2% to 20%. As a result,
doses of CMVpp65 peptide-speciﬁc T cells ranged from 1 to
15  104 IFNgþ T cells/kg and were not well correlated with
the total T cell doses administered from each CMVpp65CTL
line.
The TCR Vb phenotype of tetramerþ CMVpp65CTLs was
also analyzed in CTL lines responding to epitopes for which
HLA peptide tetramers were available. These tetramerþ
CMVpp65CTLs demonstrated an oligoclonal TCR Vb reper-
toire, with the majority of epitope speciﬁc T cells bearing Vb
segments from 1 to 3 TCR Vb families (Table 3).
Clinical Outcomes and Toxicities
Infusions at each dose level were well tolerated. No pa-
tient experienced fever, alterations in vital signs, or other
toxicities over the course of the ﬁrst 48 hours of observation.
No patient developedmanifestations of de novo acute GVHD.
Furthermore, neither of the 2 patients who had GVHD (UPNs
2 and 13) before infusion exhibited an exacerbation or
worsening of their GVHD.
As summarized in Table 4, clearance of CMVwas observed
in 14 of 16 patients. Five patients had presumed or docu-
mented CMV disease before adoptive therapy. Two with
documented CMV retinitis cleared their disease. Of the 3
patients with interstitial pneumonia, UPN 7 failed to respond
over 31 days follow-up and died of pneumonia without
clearing CMV. UPN 1 cleared CMV viremia within 14 days of
infusion but died of pneumonia 36 days after CTL infusion.
Bronchoalveolar lavage obtained in the week before herdeath was positive forMycobacterium avium but negative for
CMV. UPN 6 exhibited delayed clearance of CMV anti-
genemia, with persisting interstitial pneumonia. She cleared
her CMV viremia by 47 days after infusion but died of
persistent pneumonia 12 days later. Bronchoalveolar lavage 7
days earlier was CMV negative.
Of 11 patients who received CMVpp65CTL as treatment
for viremia persisting despite antiviral treatment, 10 cleared
their viremia. In 1 patient (UPN 13), CMV viremia was not
cleared but reduced from 3649 to< 500 copies CMV DNA/mL
by 21 days after infusion (day 109 after HCT). This patient
subsequently received steroids for pre-existing grade 2 in-
testinal GVHD. CMV viremia recurred; the patient subse-
quently died of sepsis 132 days after infusion.
Of the 16 patients, 12 were still maintained on antiviral
drugs for periods of 15 to 36 days after T cell infusion.
However, for 4 patients (UPNs 4, 5, 8, and 11), antiviral drugs
were discontinued within 1 (UPNs 4, 5, and 11) or 3 weeks
(UPN 8) of receiving CMVpp65CTL because of intolerable
drug induced toxicities. Despite this, all cleared their viremia,
including UPN 5, who had advanced retinitis before initiation
of T cell infusions.
Alterations of Circulating CMV-speciﬁc T Cells after
Adoptive T Cell Transfer and Their Correlation with CMV
Viremia
Results of sequential quantitation of IFNgþ T cells and/or
CMVpp65-HLA tetramers are summarized in Table 5. Of 16
patients, 5 (UPNs 1, 2, 11, 15, 16), had low but detectable
CMVpp65-speciﬁc IFNgþ T cells before T cell infusion. In
comparison, 6 of 9 patients (UPNs 1, 2, 3, 5, 14, 16) expressing
HLA-A*0201, A*2402, or B*0702 had quantiﬁable tetramerþ
CMVCTL before CMVpp65CTL infusion, including 2 of 10
patients without detectable IFNgþ CMVCTL.
After infusion of the CMVpp65CTLs, 15 of 16 patients
adequately tested had detectable increases in IFNgþ CMVCTL
to levels 100/106 PBMC in the blood. Such increments were
detected within 1 week after infusion in 9 of 16 patients but
were not detected until 2 to 4 weeks in 4 patients and 16
weeks in 1 (UPN 13). IFNgþ T cells did not increase to  100/
106 after infusion in 1 patient (UPN 7). UPN 7 and UPN 13 did
not clear CMV viremia. UPN 7 ultimately died of CMV
infection; UPN 13 had a late T cell response. She died of a
secondary infection, but still had CMV viremia.
Of 9 patients inheriting HLA-A*0201, A*2402, or B*0702
tested, 8 exhibited increments in CMVpp65 tetramerþ-T cells
after infusions of CMVpp65CTLs inwhich T cells restricted by
1 of these alleles were immunodominant. These increments
were detected by 1 week after infusion in 7 patients
(including all 7 with detectable tetramerþ cells preinfusion)
and by 2 to 4 weeks in 2 of the patients. UPN 6, who received
CMVpp65CTLs codominantly restricted by an overlapping
peptide presented by HLA-A*2402 and DRB1*0401, did not
generate HLA-A*2402/CMVpp65 tetramerþ T cells after
infusion but did develop IFNgþ CMVCTL. Three patients
(UPNs 3, 4, 5) who received CMVpp65CTLs that selectively
exhibited reactivity against CMVpp65 epitopes presented by
HLA-B*0702 (Table 1), developed 2 CMVCTL populations; 1
speciﬁc for the epitope targeted by the infused T cells pre-
sented by HLA-B*0702 allele and the other speciﬁc for the
NLV epitope presented by HLA A*0201. Although responses
to the epitope presented by HLA-A*0201 were markedly
lower than those to the epitopes presented by HLA-B*0702 in
patients UPNs 4 and 5, the HLA A*0201 restricted response
was dominant after CMVpp65CTL infusion, in patient UPN 3,
Table 3
Characterization of CMV pp65-Speciﬁc CTLs Administered
UPN Total T cells/kg CD8, % CD4, % Epitope TCR Vb Tetramer-positive CD8 Interferon ge Positive CD3 Cytotoxicity Dominant/
Subdominant
% Abs# infused/kg/dose %CD62L, CCR7(þ)/
%CD62L, CCR7()
% Abs# infused/kg/dose % HLA Restriction
1 5  105 78 12 QYDPVAALF 5.1 4 2  104 0/100 3.2 1.6  104 38 A2402
2 5  105 97 9 NLVPMVATV 13.1 71 35  104 2/98 20 10  104 42 A0201
3 5  105 85 15 RPHERNGFTV 7.1, 13.2 7 3.5  104 0/100 5 2.5  104 47 B0702
4 1  106 92 8 TPRVTGGGAM 7.1, 17.1 12 12  104 3/97 15 15  104 61 B0702
5 1  106 68 32 TPRVTGGGAM
RPHERNGFTV
7.1, 17.1, 8, 21.3, 14 5
2
5  104
2  104
2/98 3 3  104 54 B0702
6 1  106 86 14 QYDPVAALF 5.2, 8 3 3  104 1/99 2 2  104 18
12
A2402/DRB1 0404
7 2  106 64 36 QPFMRPHER N/D N/A - - 4 80  104 21
14
11
DRB1 0301/C0601, A0301
8 2  106 87 13 RPHERNGFTV
TPRVTGGGAM
5.1, 1
7.1, 17, 1
11
5
22  104
10  104
4/96
3/97
9
-
18  104
-
51
-
B0702
-
9 2  106 42 58 QIFLEVQAIRET N/D N/A - - 3 6  104 35
15
DRB1 1501/B3508
10 2  106 Not tested - - - - - - - - - -
11 2  106 82 18 NVSVNVHNPTG N/D N/A - - 10.3 20.6  104 17
15
B2704/DRB1 1202
12 1  106  3 88 12 PTFTSQYRIQG N/D N/A - - 9 9  104  3 71
25
33
A0101 B0801/DRB1 0301
13 1  106  3 78 22 FVFPTKDVAL N/D N/A - - 13 13  104  3 18 B3502
14 1  106  3 97 3 NLVPMVATV/ QARLTVSGLA 13.6, 21 6 6  104  3 - 2.4 2.4  104  3 42
18
A0201/B5201
15 1  106  3 92 8 GVMTRGRLKA N/D N/A - - 1.2 1.2  104  3 29 B0705
16 1  106  3 91 9 NLVPMVATV 13.1, 14 42 42  104  3 3/97 9 9  104  3 48 A0201
N/D indicates not determinable; N/A, not available.
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Table 4
Responses to Adoptive Transfer of pp65-Speciﬁc CTLs
UPN Course of CMV Infection after T Cell Transfer Clearance from Time of CTL Infusion
(and from HCT) and Cause of Death
until Last Observation
Additional Observation
Before Infusion Two Weeks After Four Weeks After Eight Weeks
After
1 >100 cells/slide 13 cells/slide Negative NE Death, interstitial pneumonia
36 d after infusion (d 200 after HCT)
BAL culture before death þ for M. avium: CMV negative;
Succumbed day 36
2 5 cells/slide 17 cells/slide Negative Negative Clearance of CMV viremia
4 wk after infusion (d 180 after HCT)
Death, complication of GVHD
464 days after SCT
3 19 cells/slide 20 cells/slide 2 cells/slide Negative Clearance of CMV viremia
8 wk after infusions (d 172 after SCT)
Death, pulm failure due to hepato-pulm syndrome:
secondary to VOD, 225 days after SCT
4 33 cells/slide Negative Negative Negative Clearance of CMV viremia
2 wk after infusion (d 140 after HCT)
Completed follow-up on protocol e remains in long-term
follow-up > 4 yr after HCT
5 24 cells/slide 14 cells/slide 19 cells/slide Negative Clearance of CMV viremia
7 wks after infusion (d 187 after HCT)
Completed follow-up on protocol e remains in long-term
follow-up > 4 yr after HCT
6 >100 cells/slide >100 cells/slide >100 cells/slide Negative Clearance of viremia
47 days after CTL infusion (d 181 after HCT)
Death, pulmonary failure: BAL d 182 culture positive for panresistent
Enterococcus; CMV negative; died 193 d after HCT
7 >100 cells/slide >100 cells/slide >100 cells/slide NE Death, pneumonia/CMV
31 d after CTL infusion (d 129 after HCT)
Death, pneumonia; unclear etiology/CMV probable 129 d after HCT
8 35 cells/slide 65 cells/slide 65 cells/slide 1 cell/slide Clearance of CMV viremia
By 9 wk after CTL infusion (d 175 after HCT)
Relapse of AML; 9 mo after HCT; died 588 d after HCT
9 PCR: 100 copies/
mL (87,900 in CSF)
PCR: 100 copies/
mL (18,900 in CSF)
Negative Negative Clearance of CMV viremia
By 4 wk after HCT (d 127 after HCT)
Completed follow-up on protocol e remains in long-term
follow-up > 3 yr after HCT
10 PCR: 100 copies/mL Negative Negative Negative Clearance of CMV viremia
2 wk after CTL infusion (d 164 after HCT)
Relapse of AML; 9 mos after HCT; died 342 d after HCT
11 PCR: 1323 copies/mL Negative Negative Negative Clearance of CMV viremia
2 wk after CTL infusion (d 92 after HCT)
Completed follow-up on protocol e remains in long-term
follow-up < 2 yr after HCT
12 PCR: 1427 copies/mL PCR: 1342 copies/mL PCR: 1191 copies/mL Negative Clearance of CMV viremia
8 wk after CTL infusion (d 160 after HCT)
Relapse of Mantle cell lymphoma; 19 mo after SCT; died 610 d after SCT
13 PCR: 3469 copies/mL PCR: 720 copies/mL Detected, but
< 500 copies/mL
PCR: 1150
copies/mL
Reduction of CMV viremia
21 days after CTL infusion (d 109 after HCT)
Death by fungal and mycobacterial infections 220 d after HCT;
still CMV viremic
14 PCR: 53,320 copies/mL PCR: 9394 copies/mL PCR: 13,710 copies/mL Negative Clearance of CMV viremia
8 wk after CTL infusion (d 201 after HCT)
Developed hemolytic anemia d270 after HCT
Treated with high-dose steroids; CMV reactivated with CMV encephalitis,
from which he died 342 days after HCT
15 PCR: 637 copies/mL Negative Negative Negative Transient clearance of CMV infection by 2
wk after CTL infusion. Patient reactivated
approximately 8 wk after initial CTL infusion
has received 2 add’l cycles of CMV CTLs.
Clearance of CMV viremia 4 wk after third
cycle of CTL infusion (d 259 after HCT)
Patient remains CMV PCR negative 18 mo after 3rd cycle of CMVCTLs
16 PCR: 3300 copies/mL PCR: 76,900 copies/mL PCR: 40,100 copies/mL Negative Clearance of CMV viremia
8 wk after CTL infusion (d 161 after HCT)
Patient remains CMV PCR negative >20 mo after CMVCTLs
NE indicates not examined; BAL, bronchoalveolar lavage; pulm, pulmonary; VOD, veno-occlusive disease.
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Table 5
Characterization of T Cell Responses to CMV pp65 after Infusion of CMVCTLs
UPN Analysis
TET/IFN
Absolute Number of CMV-Speciﬁc CTL/106 PBMC after T Cell Transfer
Before
Infusion
One Week
After
Two Weeks
After
Four Weeks
After
Six Weeks
After
Eight Weeks
After
16 Weeks
After
32 Weeks
After
1 A24 60 510 80 D D D D D
IFN 60 280 10 D D D D D
2 A2 200 900 1800 2200 3900 4200 1400 900
IFN 120 400 500 1400 1100 1800 900 500
3 A2 50 600 170 740 760 2500 2000 1200
B7 120 530 80 430 140 1000 720 400
IFN 0 360 44 30 60 800 2700 800
4 A2 0 50 100 70 0 200 50 100
B7 0 1764 2200 90 533 6100 8400 11800
IFN 0 172 240 100 400 2900 3300 4700
5 A2 0 0 0 100 310 700 250 50
B7 30 50 700 1700 5100 3200 800 300
IFN 0 20 120 200 500 612 196 330
6 A24 0 0 0 0 NP D D D
IFN 0 60 190 52 NP D D D
7 NT NT NT NT NT NT NT NT NT
IFN 0 0 60 0 D D D D
8 B7 0 0 0 900 2100 600 1522 D
IFN 0 0 0 200 460 340 600 D
9 NT NT NT NT NT NT NT NT NT
IFN 0 0 30 133 110 82 0 D
10 NT NT NT NT NT NT NT NT NT
IFN 0 70 40 200 120 192 D D
11 NT NT NT NT NT NT NT NT NT
IFN 0 256 384 480 512 352 160 320
12 NT NT NT NT NT NT NT NT NT
IFN 0 2200 830 732 300 400 3050 1100
13 NT NT NT NT NT NT NT NT NT
IFN 0 5 3 15 40 80 290 140
14 A2 860 2246 435 2423 8629 5707 2912 NP
IFN 0 270 140 822 2308 1711 1240 NP
15 NT NT NT NT NT NNTT NT NT NT
IFN 92 2369 1130 1560 498 325 246 269
16 A2 45 180 1485.96 1824 2600 9250 NP NP
IFN 30 162 748.2 775.2 1170 5365 NP NP
Tet indicates HLA peptide tetramer; IFN, T cell Interferon g analysis; NT, no tetramer available; NP, not performed; D, deceased.
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epitope presented by HLA-A*0201 detected in the patient
before CMVpp65CTL infusion.
The kinetics of expansion of the CMVCTL after infusion
and their correlation with alterations in CMV viremia are
illustrated by 3 representative patients, UPN2, UPN5, and
UPN8 (Figures 1 through 3). As shown in Figure 1, of the T
cells administered to UPN2, 71% bound HLA-A*0201/NLV
tetramers (Figure 1A). Infusion of these T cells was initially
followed by a peak of CMV antigenemia followed by an
abrupt fall to undetectable levels that was contemporaneous
with the detection of expanding populations of CMVpp65/
HLA-A*0201 tetramerþ cells in the blood (Figure 1D,G,E).
UPN 8 received a single infusion of 2106 CMVpp65CTLs/
kg after failing to respond to ganciclovir or foscarnet. The
IFNgþ T cells in this line selectively responded to the RPHER
and TPR peptides of CMVpp65 presented by HLA B*0702 and
could be tracked by their binding of RPHER/HLA B*0702
tetramers after infusion. As shown in Figure 2, after T cell
infusion, CMV antigenemia transiently increased, but then
cleared as the concentration of tetramerþ cells increased in
the blood.
The CMVpp65CTLs infused into UPN5 (Figure 3) were also
speciﬁc for these 2 epitopes presented by HLA-B*0702; 4.2%
of the T cells bound HLA B*0702 tetramers bearing the TPR
peptide and .2% bearing the RPHER peptide (Figure 3B).
CMVpp65CTLs were administered after failed treatment with
Valcyte (Genentech, San Francisco, CA) and initiation offoscarnet, at maintenance dosing only, because of associated
toxicity. Again, reduction of CMV antigenemia was observed
only with the emergence of TPR/HLA-B*0702 tetramer-
binding CMVCTL and cleared 2 weeks after infusion, at which
time foscarnet maintenance was stopped. Thereafter, the
patient remained free of CMV antigenemia (Figure 3A).
Levels of TPR/HLA-B*0702 tetramerþ cells decreased by 16
weeks after infusion but have remained detectable
throughout follow-up. In addition, by day 90 after infusion
(Figure 3C), limited numbers of HLA-A*0201-restricted T
cells speciﬁc for the NLV peptide were also detectable. At 2
years after infusion (Figure 3D) T cells speciﬁc for TPR and
RPHER are still prominent, as are the NLV speciﬁc T cells ﬁrst
detectable at day 90.
To further delineate the contribution of the adoptively
transferred CMVpp65CTLs to the CMVCTL detected after
CMVpp65CTL infusions, we examined the TCRs of isolated
MHC-peptide tetramerþ Tcells for their Vb usage as shown in
Figure 4. The TCR Vb characteristics of the tetramerþ CMVCTL
isolated from the blood of UPNs 2, 3, 4, 5, and 8, 28 to 35 days
after infusion closely matched those of the tetramerþ
CMVpp65CTLs infused. For example, the CMVpp65CTLs
infused into UPN 2 were speciﬁc for the NLV peptide pre-
sented by HLA-A*0201. The NLV/HLA-A*0201 tetramerþ
CMVpp65CTLs predominantly expressed TCRs bearing
Vb13.1. At day 28 after transfusion, the NLV/HLA-A*0201
tetramerþ CMVCTL detected in the blood were almost
exclusively Vb13.1þ T cells. Similarly, the Vb repertoires of the
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minant TPR and RPHER epitopes isolated from the blood of
patients 4 and 8matched those of the CMVpp65CTLs infused.
Although RPHER/HLA B*0702 tetramerþ CMVCTL isolated
from the blood of UPNs 5 and 8, and TPR/HLA B*0702 tet-
ramerþ CMVCTL in UPN 4, still contained a predominance of
CMVCTL bearing TCRs with the same Vbs 90 to 120 days after
infusion, CMVCTL bearing other Vbs are also in evidence. In
UPN 5, T cells binding NLV/HLA-A*0201 tetramers that were
not detected in the CMVpp65CTLs infused were also present.
Taken together, these data support the hypothesis that the T
cells responding to and clearing CMV viremia early after
adoptive transfer are the CMVpp65CTLs infused, whereas
CMVCTL detected late after infusion are a mix of the
CMVpp65CTLs transfused and other CMVCTL generated from
expansion of undetected small populations of CMVCTL in the
transferred cells, expansion of T cells from residual mature
CMVCTL in the patient’s transplantation, or new CMVCTL
developing from precursors in the graft that mature in the
host thymus.
We similarly assessed the activity of third-party donor-
derived CMVpp65CTLs in 1 patient. UPN 17 received an un-
modiﬁed (HLA-A) mismatched unrelated transplant from a
CMV-seronegative donor at another center. CMV viremia
developed after transplantation but failed to respond to
antiviral therapy. The patient’s CMV was found to be resis-
tant to foscarnet, ganciclovir, and cidofovir by mutational
analyses. As shown in Figure 5, this patient received 3weekly
doses of 1  106 third-party CMVpp65CTLs/kg that were
matched for 2 HLA alleles and speciﬁc for the NLV peptide
presented by the HLA-A*0201 allele shared by patient,
transplant donor, and third-party CMVpp65CTL donor. After
the ﬁrst infusion, CMV DNA rose to 800,000 copies/mL blood
but then declined after the second dose and subsequently
cleared 21 days after the third dose of HLA-A*0201/NLV-
restricted third-party CMVpp65CTLs. Figure 5C illustrates
the corresponding incremental increase in HLA-A*0201/NLV
tetramerþ CMVCTL frequencies in the patient’s blood from
.7% on day þ14 to 5.6% on day þ150 after infusion. We also
documented an increase in the IFN-gþ T cell frequencies
responding to the total pool of CMVpp65 peptides and,
speciﬁcally, the NLV peptide to 1.5% by day þ49.
DISCUSSION
In 2005, our group described a technique for generating
CMVpp65CTLs based on sensitization of HCT donor-derived T
cells with autologous CAMS loaded with a pool of 138
synthetic 15-mer peptides spanning the sequence ofFigure 1. Induction of clinical response after infusion of donor-derived HLA-A*0201
characterization before infusion for UPN 2 is shown. (A) Aliquots of 105 T cells labeled w
or HLA-B*0702-TPR (control) tetramers were analyzed via FACS. (B) Functional charac
quantitating the proportion of CD8þ T cells generating IFN-g upon overnight stimul
subpools containing speciﬁc CMVpp65 pentadecapeptides. An overlapping grid of the
cells were seen in response to targets loaded with pool 3 and 23 corresponding to the
cell cytotoxic activity are shown. A panel of peptide loaded EBV BLCLs sharing a single H
to deﬁne the HLA restriction. The T cells shownwere exclusively cytotoxic against HLA
(D-F) UPN 2. Analysis of CMVpp65-speciﬁc T cells after CMV CTL infusion. (D) Tetrame
at day 28 and 210 after infusion. Distinct populations of HLA-A*0201-NLV tetramer
tetramer. (E) Cytokine release assay is shown at day 45 after CTL infusion demonstr
gous NLV peptide-loaded PBMC. (F) The cytotoxic activity of T cells recovered from pat
assay against an HLA-A*0201 [þ] human ﬁbroblast cell line (MRC5) either uninfected,
cell donor as well as HLA mismatched BLCLs either alone or loaded with the NLV pepti
after infusion is shown for UPN 2. The arrow indicates the time of infusion of the
performed twice each week. The number of CMV-speciﬁc T cells detected after infusio
PBMC of blood (y) and IFN-gþ CD3þ T cells/106 PBMC of blood (D) detected at day 0CMVpp65 [21]. We selected CMVpp65 because of the many
proteins generated by CMV, CMVpp65 induces T cell re-
sponses of the greatest magnitude and in the highest pro-
portion of individuals, the second most immunogenic being
the immediate early antigen 1 (IE-1) [32-34]. More recent
studies also indicate that presentation of CMVpp65 peptides,
which does not require new protein synthesis, may be less
susceptible to inhibition by subsequently generated evasins,
the noncoding RNAs generated by CMV that can interfere
with antigen processing and transporter associated with
antigen processing (TAP)-mediated transport of antigen
peptides to HLA alleles for presentation [35,36].
In this phase I trial, we tested the activity of transplant
donorederived T cells sensitized with the pool of over-
lapping 15-mer peptides of CMVpp65 in a series of allogeneic
HCT recipients who had either clinically overt infection or
CMV viremia persisting despite prolonged treatment with
antiviral drugs. As shown in Table 2, only 1 patient had
received less than 2 antiviral drugs. All had been treated for
periods of 7 to 18 weeks and at time of adoptive transfer had
stable or increasing levels of CMV antigenemia or CMV DNA
in the blood, despite antiviral therapy. Such patients have
been reported to have a markedly increased mortality due to
CMV disease and associated infections [37-39].
The CMVpp65CTL infusions, at all doses, were well
tolerated without clinical toxicities. Furthermore, no patient
developed de novo acute or chronic GVHD or a ﬂare of
existing GVHD after adoptive transfer. This ﬁnding is similar
to our own and other reported experiences with adoptive
transfer of EBV-speciﬁc T cells sensitized with autologous
EBV BLCL over 3 to 5 weeks in vitro [40-43] to deplete allo
responsive T cells.
Of the total of 17 patients treated, all but 2 (UPNs 7 and
13) achieved durable clearance of CMV viremia. Of the 3
patients treated who had interstitial pneumonia at time of
ﬁrst infusion, 2 cleared CMV (UPNs 1 and 6) but all 3 ulti-
mately died of complications of interstitial pneumonia, 1
with a concurrent mycobacterium avium intracellulare (MAI)
infection (UPN 1). Feuchtinger et al. [44] have also reported
continued pulmonary deterioration despite clearance of
CMV. These ﬁndings raise concerns that treatment with
CMVCTL may initially augment inﬂammatory responses in
infected tissues resulting in additional tissue damage. On the
other hand, UPN 5 and UPN 9 each had documented CMV
retinitis that cleared without residual retinal damage.
Although groups of patients received escalating total
doses of CMVpp65CTLs ranging from .05 to 2.0  106/kg, the
actual doses of CMVCTL provided at each dose level, asrestricted NLV epitope-speciﬁc CMV CTLs in a viremic patient. (A-C) CMV CTL
ith anti-CD3 FITC and anti-CD8 PE as well as APC conjugated HLA-A*0201-NLV
terization and epitope mapping was performed for the CTLs before infusion by
ation with aliquots of autologous PBMC, each loaded with 1 of 24 individual
peptide subpools permitted epitope identiﬁcation. As shown, IFN-gþ CD8þ T
NLV peptide. (C) The in-vitro cytotoxicity and the HLA allele restriction of the T
LA allele with the T cell donor were used in a 4-hour 51chromium release assay
-A*0201 sharing targets loaded with CMVpp65 peptide pool or the NLV peptide.
r analysis is shown for T cells directly obtained from patient’s peripheral blood
binding T cells are demonstrated in comparison to a control HLA-B*0702-TPR
ating CD8þ IFN-gþ T cells in response to overnight stimulation with autolo-
ient’s blood 45 days after CTL infusion was tested in vitro in a chromium release
or CMV AD169 infected or loaded with the NLV peptide. PHA blasts from the T
de were used as controls. (G) Clinical response and in vivo kinetics of CMV CTLs
CMV CTLs. The clinical response was followed by CMV antigenemia assay (n)
n is plotted as the absolute number of HLA A*0201-NLV tetramer [þ] T cells/106
, 1, and 7 and weekly thereafter.
Figure 2. HLA-B*0701 restricted T cells induce disease clearance.
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T cells, varied considerably (Table 3). However, we did not
discern a relationship between clinical and/or viremic
response and doses of CMVpp65CTLs/kg administered or the
absolute doses of CMVCTL provided. On the other hand,
clinical response was consistently correlated with expansion
of CMVpp65-reactive T cell populations in vivo. These in-
crements in the frequencies of CMVCTL were detected as
early as day 7 and usually peaked by day 28. After clearance
of CMV, CMVCTL levels fell to steady states that were
maintained through 5 to 24 months of observation. In
contrast, the 2 patients who failed to clear CMV had no sig-
niﬁcant increments in the frequencies of circulating CMVCTL.
Failure of in vitroeselected CMVpp65CTLs to proliferate
after adoptive transfer has also been correlated with treat-
ment failure by other groups [17,20,45], providing evidence
both for the need to expand effector T cell populations to
achieve viral clearance and the therapeutic potential of even
small numbers of effector cells if they replicate sufﬁciently
in vivo [44]. However, the factors contributing to a lack of
proliferation are still poorly deﬁned. In recipients of un-
modiﬁed HCT treated for CMV, ongoing treatment of GVHD
with immunosuppressive drugs, particularly glucocorticos-
teroids, has been implicated [2,46]. However, in our series, all
but 2 patients received T cell depletedetransplants admin-
istered without immunosuppressive drug prophylaxis. In
trials exploring adoptive T cell therapy for EBV-associated
lymphomas complicating allogeneic HCT, failure of T cells
to expand in vivo has also been correlated with treatment
failure and has been ascribed to the inability of transferred T
cells to recognize the EBVþ lymphoma cells either because
the EBV epitope targeted by the T cells is deleted or mutated
[40,47] or, in HLA-disparate patients, because the T cells
transferred are restricted by an HLA allele not shared by the
tumor. Thus far, mutations in immunogenic peptides of
CMVpp65 that would affect their recognition by HLA-
restricted CMVpp65-speciﬁc T cells have been found to be
infrequent among clinical isolates [48]. However, CMV has
developed a multitiered array of microRNAs, termed evasins,
that can prevent the recognition or killing of infected cells by
T cells. For example, evasins such as US2, 3, 6, and 11 can
disrupt the membrane localization and stability of speciﬁc
MHC class I alleles, thereby impairing their expression[35,49,50]. US3 and US6 can also prevent the transport and
loading of processed peptides on HLA class I alleles for pre-
sentation to T cells [36]. In addition, Kim et al. [51] have
recently shown that a CMV micro RNA US4-1 can down-
regulate the expression of an aminopeptidase essential to the
editing of antigenic peptides during their processing within
the endoplasmic reticulum. Unfortunately, we did not have
infected cells or the viral isolates from the 2 patients who
failed to clear CMV to examine whether 1 or more of these
mechanisms may have contributed to the apparent failure of
the transferred Tcells to recognize and expand in response to
infected cells in the host.
Recently, other groups have also employed CMVpp65 15-
mer peptide pools to stimulate the propagation of CMV-
speciﬁc T cells. Thus, Bao et al. [52] employed overlapping
peptides of CMVpp65 and IE-1 to generate transplant
donorederived CMV-speciﬁc T cells for treatment of CMV
viremia persisting despite antiviral treatment for >2 weeks
in 7 patients, including 5 who had received T celledepleted
haploidentical grafts. Of these, 3 cleared CMV viremia and 3
had signiﬁcant reduction of viral load, each associated with
increments in circulating levels of CMV-speciﬁc T cells. More
recently, Peggs et al. [53] and Feuchtinger et al. [44] evalu-
ated donor-derived CMV-speciﬁc T cells rapidly generated
from the blood by sensitization for 16 hours with a pool of
overlapping CMVpp65 peptides, followed by immunose-
lection of interferon geproducing T cells. The median doses
of CMVpp65-speciﬁc T cells obtained and administered by
this approach are low (2 to 10  103/kg), which limits anal-
ysis of their speciﬁcities. Nevertheless, as shown by Feuch-
tinger et al. [44], such T cell doses can induce durable
clearance of CMV in 50% to 60% of allogeneic HCT recipients
with CMV infection or persistent viremia who have failed to
respond to antiviral drugs. Furthermore, Peggs et al. [53]
reported that over 90% of patients treated preemptively for
CMV viremia with such T cells clear infection after no or only
2 to 3 weeks treatment with a single antiviral drug. In both
studies, in vivo expansion of CMVpp65-speciﬁc CD4þ and/or
CD8þ T cells was also correlated with response.
The group at Baylor College of Medicine has explored T
cells simultaneously sensitized to antigens from multiple
viruses, including CMVpp65 and IE-1 to elicit CMV-speciﬁc T
cell responses. Initially, they used autologous dendritic cells
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the expression of CMVpp65, and adenovirus proteins [54]
and, more recently, PBMC loaded with pools of overlapping
15-mer peptides from 5 viruses (Adenovirus, EBV, CMV, BK,
and human herpes virus 6) [55] to sensitize donor T cells. In
initial trials, both approaches have shown promise in
limiting viremia [55,56] and clearing CMV infection or drug-
refractory viremia [54,55] as well as concurrent infections
due to other targeted viruses [55]. In the trial of T cells
sensitized with pooled peptides from 5 viruses, all of the T
cell cultures from seropositive donors generated T cells
speciﬁc for CMVpp65 or IE-1. This approach has the advan-
tage of addressing infections from each of the viruses most
often associated with disease in HCT recipients. However, T
cells responding to immunogeneic peptides from different
viruses in the pool may also recognize epitopes presented by
different HLA alleles on the antigen presenting cells.
Although such donor-derived T cells would be expected to
consistently include donor T cells speciﬁc for viral peptides
that are restricted by HLA alleles expressed by infected cells
from an HLA-matched recipient, they would not be active in
an HLA-disparate patient unless the virus-speciﬁc T cells are
restricted by an HLA allele shared by infected cells of the
host. Thus, in HLA disparate hosts, the utility of such cells
may be limited unless the HLA restrictions of the T cells
speciﬁc for each virus are identiﬁed.
For our study, we identiﬁed both the epitope speciﬁcity
and HLA restriction of the CMVpp65-speciﬁc T cells so as to
gain information regarding the relative immunogenicity of
the peptides and to be able to track the responding T cells
after infusion and correlate their growth in vivo with clin-
ical activity. Despite the fact that the T cells were sensitized
with a pool containing a broad array of CMVpp65 epitopes,
of 138 15-mers, the CMVpp65CTLs generated over the 4 to 5
week course of in vitro culture consistently responded to
only 1 to 3 peptide epitopes presented by 1 or more class I
or II HLA alleles expressed by the donor (Table 3, Figure 1B).
Analysis of the TCR Vb usage of tetramerþ T cells speciﬁc for
these epitopes also revealed them to be oligoclonal
(Figure 4). The immunodominance of speciﬁc epitopes may
have shaped the repertoire of CMVpp65CTLs generated
in vitro. However, Kern et al. have observed a similar degree
of this immunodominance in vivo in the blood of seropos-
itive donors late after primary infection [57]. As expected
from prior reports, epitopes presented by HLA B*0702 were
dominant in all 4 donors inheriting this allele, including 3
who coinherited HLA A*0201 [58]. Similarly, the NLV pep-
tide presented by HLA A*0201 was dominant in 3 donors
inheriting HLA A*0201 who did not coinherit HLA B*0702.
All 8 recipients of CMVpp65CTLs restricted by HLA A*0201
or B*0702 cleared viremia, including 3 of 3 with retinitis or
pneumonia. In contrast, of 8 patients who received
CMVpp65CTLs restricted by other alleles, 2 failed to clear
viremia and ultimately died of infection and 1 patient (UPN
15) uniquely required 3 cycles of CMVpp65CTLs to clear
viremia.Figure 3. Sequential evaluation of T cell responses and CMV antigenemia after adopt
in vivo kinetics of CMV CTLs after infusion is shown for UPN 5 inheriting HLA-A*020
response was followed by CMV antigenemia assay (n) performed twice a week. The CM
B*0702-TPR (y) and HLA-A*0201-NLV tetramers (D) epitope speciﬁc tetramer[þ] T cells
1, and 7 and weekly thereafter. (B) Tetramer analysis of the CMV CTLs infused to p
predominantly bound to tetramers for HLA-B*0702-TPR, and also for HLA-B*0702- R
A*0201-NLV. Tetramer analysis of patient’s T cells performed at day 90 (C) and at 2 yea
to tetramers for HLA-B*0702-TPR, HLA-B*0702-RPHER, and emergence of T cells bind
=Multicenter trials that accrue large and genetically
diverse patient populations will be required to determine if
this efﬁcacy of CMVpp65CTLs generated against speciﬁc
immunodominant epitopes, such as those presented by HLA
A*0201 or B*0702, differs signiﬁcantly from that of CMVpp65
CTL speciﬁc to epitopes presented by other HLA alleles.
However, even now, the preferential expansion of T cells
responding to such immunodominant peptides should be
considered also relevant to assessments of different ap-
proaches to T cell generation for adoptive therapy. For
example, we initially expected that the use of a pool of
synthetic overlapping peptides of CMVpp65 for in vitro
generation of virus-speciﬁc T cells would have the advantage
of generating T cells against multiple immunogenic epitopes
presented by many different HLA alleles, thus providing a
broader repertoire of CMVpp65-speciﬁc T cells to combat
viral infection than that produced by sensitization with sin-
gle viral peptides [19,59] or by isolation of CMVpp65-speciﬁc
T cells directly from the blood with peptide/HLA tetramers or
streptamers [60-62]. However, our data indicate that the
repertoire generated is actually more limited than antici-
pated and support the hypothesis that small numbers of T
cells speciﬁc for single highly immunogenic immunodo-
minant epitopes may be adequate to achieve control of
viremia and resolution of infection.
On the other hand, our data also raise the possibility that
CMVpp65CTLs generated against certain less immunogenic
epitopes of CMV presented by other alleles may be less
effective, a possibility further supported by recent observa-
tions of Giest et al. [63]. Because tetramer and streptamer-
based isolation of T cells have thus far been limited to T
cells speciﬁc for the highly immunogenic and immunodo-
minant epitopes presented by no more than 5 prevalent HLA
alleles, particularly A*0201 and HLA B*0702, the excellent
responses to such T cells may not reﬂect these potential
limitations.
The technique employed for generating CMVpp65-
speciﬁc T cells in this study has several advantages,
particularly the safety of employing synthetic peptides
rather than viral products for T cell sensitization and the
consistency with which the technique induces large pop-
ulations of cytotoxic CD8 and/or CD4 T cells of required
CMVpp65-speciﬁc and depletions of allo responsive T cells
from fresh or shipped blood samples from every seropos-
itive donor in our series. However, the 4 to 5 weeks
required for in vitro generation of these CMVpp65-speciﬁc
T cells remains an impediments to timely treatment unless
the transplant donorederived T cells are generated before
or at the time of initial CMV reactivation in patients at risk.
We adapted this approach for the present study, generating
CMVpp65-speciﬁc T cells from 30 transplant donors but
only treating 16 patients with clinical infection or CMV
viremia who failed to respond to antiviral drugs. With the
speciﬁc consent of the donors, the unused T cells lines
were banked for potential use in transplantation patients
other than for the individual from whom the donorive therapy in a patient with CMV chorioretinitis. (A) The clinical response and
1 and HLA-B*0702. The arrow indicates the infusion of CMV CTLs. The clinical
V CTLs detected after infusion are plotted as the absolute number of for HLA-
/106 PBMC of blood and of IFN-gþ CD3þ (n) T cells/106 PBMC detected at day 0,
atient UPN 5 coinheriting HLA-A*0201 and HLA-B*0702 is shown. The CTLs
PHER, but did not bind to tetramers for HLA-A*2402-QYD (control) or HLA-
rs (D) after infusion of CMV CTLs is shown, which demonstrates T cells binding
ing to tetramers for HLA-A*0201-NLV.
Figure 4. Infused CMV CTLs demonstrate an oligoclonal TCR Vb phenotype represented in speciﬁc Vb families, which are also detected after infusion. The TCR Vb
phenotype of the infused tetramer positive CMV CTLs (top bar graph) was compared to the TCR Vb of the tetramer þ CMV CTLs recovered from the patient’s blood
after CTL infusion (bottom mirror image bar graph) at early and late time points.
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Figure 5. Clinical response after infusion of epitope-speciﬁc CMV CTLs from HLA partially matched third-party donors. (A) HLA typing of the patient, the HSCT donor,
and the third-party CMV CTL donor are shown. The third-party donor was matched at HLA-A*0201 and HLA-DQB1*0202 and HLA-DQB1*0602 with the patient and
donor. (B) The clinical response and in-vivo kinetics of CMV CTLs at various time points after infusion of third-party donor-derived CMV CTLs is shown. The black
arrows indicate the infusion of CTLs. The CMV copies/mL blood (n) was followed as marker for clinical response, and the CMV CTLs were detected in patient’s blood
using HLA A*0201-NLV tetramers speciﬁc for the epitope to which the infused third-party T cells were responsive. The absolute number of A*0201-NLV tetramerþ T
cells/mL (y) and of IFN-gþCD8þ T cells/mL (D) detected after infusion at day 0, 1, and 7 and weekly thereafter are plotted. (C) Tetramer analysis of T cells is shown from
the patient before infusion and days þ14, þ28, þ90, and þ150 after infusion of third-party CMV CTLs. HLA-A*0201-NLV tetramer þ T cells were not detected before
CTL infusion, but were detectable thereafter with maximal response of 5.6% at day 150 after CMV CTL infusion. (D) Intracellular IFN-g production of CD8þ cells is
shown from the patient before and on day þ90 (1.5%) after infusion of third-party CMV CTLs.
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cells lines was used to clear CMV in UPN 17. Current single
center and planned multicenter phase II trials are
comparing transplant donorederived versus HLA partially
matched, appropriately HLA-restricted third-party donor-
derived CMVpp65-speciﬁc T cells, again in the treatment
of patients with clinical disease or viremia persisting
disparate extended therapy with antiviral drugs. Initial
results from 2 centers are promising and suggest that
virus-speciﬁc third-party T cells, which are immediately
accessible and broadly applicable but have a shorter sur-
vival in vivo, may nevertheless induce clearance of infec-
tion in a majority of care [45,64].
In conclusion, adoptive transfer of transplant donor or
third-partyederived CMVpp65CTLs sensitized in vitro with a
pool of synthetic 15-mers peptides spanning CMVpp65 is
safe, does not cause GVHD, and can clear CMV infections in
high-risk patients who have failed prolonged therapy with
antiviral drugs. Strikingly, the CMVpp65CTLs generated
consistently exhibited speciﬁcity for 1 to 3 immunodominant
epitopes presented by a limited number of class I or II HLA
alleles. In responding patients, transplant donorederived
CMVpp65CTLs proliferate and can be detected for periods of120 days to up to 2 years after infusion, thereby providing
sustained resistance to this pathogen.
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